Subscribe Sign In Register

Jeffrey Ubben

2017-07-alpha-stephen-taub-value-act-valeant-pharmaceuticals-small.jpg
Premium
Jeffrey Ubben’s ValueAct Continues to Surge Despite its Valeant Stake
Stephen Taub
July 14, 2017
Portfolio
The Morning Brief: Corporate Execs, ValueAct’s Ubben Unveil Governance Principles
Amanda Cantrell
July 22, 2016
valeant-anchor.jpg
Premium
ValueAct’s Valeant Problem
July 21, 2016
Portfolio
The Morning Brief: Valeant Surges, but Big Problems Remain
Stephen Taub
March 22, 2016
Premium
Keeping Tabs on the Damage from a Cratering Valeant
Stephen Taub
March 21, 2016
Premium
Valeant’s Winners and Losers
Stephen Taub
March 16, 2016
Premium
ValueAct Grows Its Cash Pile, but Not for Dry Powder
Stephen Taub
March 7, 2016
Premium
ValueAct Is Seeking Longer-Term Capital
Stephen Taub
November 24, 2015
bill-ackman-thumbnail.jpg
Premium
ValueAct, TCI Faring Better than Most Activists
Stephen Taub
October 9, 2015
Portfolio
The Morning Brief: ValueAct’s Ubben to Join 21st Century Fox Board
Stephen Taub
September 30, 2015
jeffrey-ubben-small.jpeg
Premium
Good Guys: Jeffrey Ubben And the Value of Crowds
Danielle Beurteaux
September 22, 2015
Portfolio
The Morning Brief: Valiant Capital Scrambles Toward Break-even
Stephen Taub
June 18, 2015